RealTime Dynamix™: Multiple Sclerosis EU Q1 2018 Spotlight
Early launch of Roche’s Ocrevus has surpassed Mavenclad due to first-in-market primary progressive multiple sclerosis label and broad access through compassionate use programs, although transitioning to country-level health plans may slow future momentum, according to a new report from Spherix Global Insights. Neurologists surveyed in Q3 2017 anticipated a 45% prescriber base and 2.5% share of disease-modifying therapy (DMT)-treated patients by this time, but actual Mavenclad use reported by EU neurologists (n=262) has not changed over the past six month. See complimentary highlights from our bi-annual tracker of the EU MS market, RealTime Dynamix™: Multiple Sclerosis EU.
Contact [email protected] for more information about the highlighted report or to see if your company already has access to the report series.
All company, brand or product names and logos in this document are trademarks of their respective holders.